Neonatal outcomes of pregnancies affected by haemolytic disease of the foetus and newborn and managed with intrauterine transfusion: A service evaluation

Blood Transfusion

Volumn 11, Issue 4, 2013, Pages 548-552

  Birchenall, Katherine A ^a   Illanes, Sebastian E ^b   Lopez, Francisco ^b   Overton, Timothy ^a   Liebling, Rachel ^a   Soothill, Peter W ^a   Abdel Fattah, Sherif ^a   Denbow, Mark ^a  

^a ST MICHAEL'S HOSPITAL   (United Kingdom)

^b UNIVERSIDAD DE LOS ANDES   (Chile)

Author keywords

Haemolytic disease; Haemolytic disease of the foetus and newborn (HDFN); Intrauterine transfusion; Neonatal outcomes; Rhesus

Indexed keywords

ALLOIMMUNIZATION; APGAR SCORE; ARTICLE; BLOOD SAFETY; CESAREAN SECTION; CLINICAL PROTOCOL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; EMERGENCY SURGERY; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; EVALUATION STUDY; FEMALE; FETUS; FETUS DISEASE; FETUS OUTCOME; FETUS WASTAGE; HOSPITAL ADMISSION; HUMAN; INTRAUTERINE BLOOD TRANSFUSION; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN ASSESSMENT; NEWBORN HEMOLYTIC DISEASE; NEWBORN INTENSIVE CARE; OUTCOME ASSESSMENT; PHOTOTHERAPY; PREGNANCY; PREGNANCY OUTCOME; RETROSPECTIVE STUDY; TREATMENT DURATION; VAGINAL DELIVERY;

ADULT; BLOOD TRANSFUSION, INTRAUTERINE; DATABASES, FACTUAL; ERYTHROBLASTOSIS, FETAL; FEMALE; GREAT BRITAIN; HUMANS; INFANT, NEWBORN; MALE; PREGNANCY; RETROSPECTIVE STUDIES;

EID: 84891939965     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.0288-12     Document Type: Article

References (13)

1. National Institute for Health and Clinical Evidence. Routine antenatal anti-D prophylaxis for women who are Rhesus D negative. Review of NICE technology appraisal guidance 41. Issue date 2008; review date 2011. Available at: http://www.nice.org.uk/nicemedia/pdf/TA156Guidance.pdf. Accessed on 05/12/2012.
2. De Boer IP, Zeestraten EC, Lopriore E, et al. Paediatric outcome in Rhesus haemolytic disease treated with and without intrauterine transfusion. Am J Obstet Gynecol 2008; 198: 54.e1-4.
3. Moise K Jr. Management of Rhesus alloimmunization in pregnancy. Obstet Gynecol 2008; 112: 164-76.
4. Illanes S, Soothill P. Noninvasive approach for the management of hemolytic disease of the fetus. Expert Rev Hematol 2009; 2: 577-82.
5. Mari G, Deter RL, Carpenter RL, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N Engl J Med 2000; 342: 9-14.
6. Van Kamp IL, Lumper FJ, Oepkes D, et al. Complications of intrauterine intravascular transfusion for fetal anemia due to maternal red-cell alloimmunization. Am J Obstet Gynecol 2005; 192: 171-7.
7. Smits-Wintjens VE, Walther FJ, Rath ME, et al. Intravenous immunoglobulin in neonates with Rhesus hemolytic disease: a randomized controlled trial. Pediatrics 2011; 127: 680-6.
8. McGlone L, Simpson JH, Scott-Lang C, et al. Short-term outcomes following intrauterine transfusion in Scotland. Arch Dis Child Fetal Neonatal Ed 2011; 96: F69-70.
9. Rath ME, Smits-Wintjens VE, Lindenburg IT, et al. Postnatal outcome in neonates with severe Rhesus c compared to Rhesus D hemolytic disease. Transfusion 2012; DOI: 10.1111/j.1537-2995.2012.03937.x.
10. Rath ME, Smits-Wintjens VE, Lindenburg I, et al. Top-up transfusions in neonates with Rh hemolytic disease in relation to exchange transfusions. Vox Sang 2010; 99: 65-70.
11. Smits-Wintjens VE, Rath ME, van Zwet EW, et al. Neonatal morbidity after exchange transfusion for red cell alloimmune hemolytic disease. Neonatology 2013; 103: 141-7.
12. National Institute for Health and Clinical Excellence. Neonatal jaundice. NICE clinical guideline 98. Issue date May 2010. Available at: http://www.nice.org.uk/nicemedia/live/12986/48578/48578.pdf. Accessed on 05/12/2012.
13. Lindenburg IT, Wolterbeek R, Oepkes D, et al. Quality control for intravascular intrauterine transfusion using cumulative sum (CUSUM) analysis for the monitoring of individual performance. Fetal Diagn Ther 2011; 29: 307-14.